By David —

(Untitled)

CATALYSTS

  • 26H1: FDA Breakthrough Therapy decision for QTORIN in cVM (mid/late June, 60-day clock)
  • 26H2: FDA alignment on cVM single-pivotal framework and pivotal study design
  • 27H1: NDA submission for QTORIN in mLM under BTD rolling review
  • 27H2: Anticipated FDA full approval of QTORIN in mLM; U.S. launch preparation
  • 27H2: Initial pipeline expansion indication selection beyond mLM and cVM

KEY EVENTS

  • Mar 2026: SELVA Phase 3 positive topline in mLM; +2.13 mLM-IGA vs placebo (p<0.001), 95% of patients improved, 86% Much/Very Much Improved, no drug-related SAEs
  • Feb 2026: Closed $215.8M follow-on offering (1.84M shares at $125.00); funds operations well past anticipated NDA filing
  • Dec 2025: TOIVA Phase 2 positive topline in cVM; clinically meaningful improvement vs placebo underpinning subsequent BTD filing
  • 4Q 2024: Completed reverse merger with Pieris Pharmaceuticals; began trading on NASDAQ under ticker PVLA
  • Jul 2023: FDA granted Breakthrough Therapy Designation for QTORIN in mLM, enabling rolling NDA review

BUSINESS OVERVIEW

  • U.S. clinical-stage rare disease biopharmaceutical company focused on developing and commercializing novel topical therapies for serious rare skin diseases
  • Lead asset QTORIN 3.9% rapamycin anhydrous gel is a proprietary topical mTOR inhibitor targeting PI3K/mTOR-driven rare skin diseases
  • Two pivotal indications: microcystic lymphatic malformations (mLM) and cutaneous venous malformations (cVM); neither has any FDA-approved therapy today
  • FY25 operating loss of ~$39M reflecting R&D investment in SELVA and TOIVA pivotal programs; no product revenue to date
  • SELVA Phase 3 pivotal topline in mLM (Mar 2026) supports NDA submission in 1H 2027 under Breakthrough Therapy rolling review
  • TOIVA Phase 2 in cVM (Dec 2025) positive; BTD request pending FDA decision mid/late June 2026 on 60-day statutory clock
  • Pro forma cash of ~$272M following Feb 2026 follow-on offering; funds operations well past anticipated mLM NDA filing and launch
  • Programmable platform applicable to >15 additional rare skin disease indications; first pipeline expansion selection expected 2027
  • Selected Investors: [to fill]

INVESTMENT THESIS

  • QTORIN 3.9% rapamycin gel targets two serious rare skin diseases with no FDA-approved therapies and combined U.S. prevalence of ~105,000 patients
  • SELVA Phase 3 delivered robust effect size (+2.13 mLM-IGA; p<0.001; 95% improved) with clean safety and minimal systemic exposure, de-risking the mLM path
  • Breakthrough Therapy Designation enables rolling NDA review without a post-approval confirmatory trial, accelerating time to commercialization in mLM
  • Programmable anhydrous gel platform applicable to >15 additional rare skin disease opportunities offers long-dated pipeline optionality beyond lead indications

CONSIDERATIONS

  • Concentrated binary single-pivotal risk across both indications; cVM regulatory path hinges on FDA BTD outcome expected June 2026 and mLM commercial execution risk as first-ever launch approaches

Key Decision Makers bios — left blank per your instruction.

A couple of flags worth checking before you paste:

  • The "4Q 2024" reverse-merger date I used as approximation; you may want to confirm the exact close month from the S-4/8-K.
  • The ~$39M FY25 operating loss is approximate — pull the exact figure from the 10-K income statement when you wire up the financials column.
  • The "~105,000 U.S. prevalence" figure assumes mLM ~30K + cVM ~75K as disclosed in corporate presentations; verify against the most recent IR deck.